Physician profile
William R Cox
NPI 1902946858
$22,970.81
in general payments reported to CMS, 2019-2025
65 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,542 · 2020: $1,762 · 2021: $3,213 · 2022: $3,131 · 2023: $4,731 · 2024: $3,913 · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,322.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,866.23 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,729.14 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $2,178.92 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $1,452.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,452.12 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $1,153.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $926.71 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $598.69 | 2021-2025 | |
| Astellas Pharma US INC | $586.76 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $578.21 | 2019-2025 | |
| Amgen INC. | $568.12 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $563.08 | 2019-2025 | Steglatro, Belsomra, Gardasil 9 |
| Mannkind Corporation | $557.00 | 2019-2023 | Afrezza |
| Janssen Pharmaceuticals, INC | $551.46 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $478.97 | 2023-2025 | Voquezna |
Show all 64 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.